Tesamorelin dosage
Also known as: Egrifta SV, Egrifta WR
What is Tesamorelin?
Tesamorelin is a synthetic version of human growth hormone-releasing factor (also called GHRH): the full 44-amino-acid natural sequence with a small chemical group added to one end. It is a prescription medicine sold in the United States as Egrifta SV and Egrifta WR by Theratechnologies, first approved by the FDA in 2010.
How it works
Tesamorelin binds the same pituitary receptors as the body's own growth hormone-releasing factor and stimulates release of natural growth hormone, which helps break down fat. This also raises IGF-1, a growth factor made in the liver and other tissues.
What the evidence shows
Tesamorelin has the strongest human evidence of the growth hormone-releasing peptides, but only for one group of patients. Two randomized, placebo-controlled Phase 3 trials enrolled about 800 adults with HIV and excess abdominal fat; over 26 weeks, visceral fat (the deep fat around the organs, measured by CT scan) fell about 15% relative to placebo, while fat under the skin did not change significantly. The label describes its effect on body weight as neutral. A separate 50-person randomized trial in people with HIV found a modest reduction in liver fat over 6 months. Long-term cardiovascular safety has not been established.
Reported side effects
- Injection-site reactions such as redness, itching, pain and bruising (25% versus 14% with placebo)
- Joint pain, muscle pain and pain in the arms or legs
- Swelling from fluid retention, sometimes with carpal tunnel syndrome
- Raised blood sugar: 5% of treated patients reached a diabetes-range HbA1c versus 1% on placebo
- Allergic reactions such as rash and hives (about 4% of patients)
- IGF-1 levels above the normal range in a substantial share of patients
Cautions
- Not to be used during pregnancy; the label lists it as contraindicated because of possible harm to the fetus.
- Not to be used by people with active cancer; the label warns of an increased risk of tumors because growth hormone is a growth factor.
- Not to be used by people whose pituitary gland has been damaged by surgery, a tumor, radiation or head injury.
- Safety and effectiveness have not been established in children, and there is no information in people over 65.
- Egrifta SV and Egrifta WR are different formulations and are not substitutable for one another.
Legal and regulatory status
Tesamorelin is FDA-approved, by prescription, for one use: the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is not indicated for weight loss management. USADA lists tesamorelin as prohibited in sport at all times.
Common questions
What is tesamorelin approved for?
The FDA approved it to reduce excess abdominal fat in adults with HIV who have lipodystrophy, a change in body fat distribution. That is its only approved use.
Is tesamorelin a weight loss drug?
No. The FDA label states it is not indicated for weight loss management and describes its effect on body weight as neutral.
Can tesamorelin raise blood sugar?
Yes. In clinical trials, 5% of people taking tesamorelin reached an HbA1c in the diabetes range compared with 1% on placebo, and the label calls for blood sugar to be checked before and during treatment.
Sources
- FDA: Egrifta WR (tesamorelin) prescribing information, revised March 2025
- DailyMed: Egrifta WR (tesamorelin) label
- DailyMed: Egrifta SV (tesamorelin) label
- New England Journal of Medicine (2007), PubMed record 18057338: Metabolic effects of a growth hormone-releasing factor in patients with HIV
- Journal of Clinical Endocrinology and Metabolism (2010), PubMed record 20554713: Pooled analysis of two Phase 3 tesamorelin trials
- JAMA (2014), PubMed record 25038357: Tesamorelin, visceral fat and liver fat in HIV
- USADA: Anthony McCauley accepts doping sanction
Tesamorelin reviews and Q&A
No reviews or questions yet. Be the first.
Get the printable dosing chart
All 50 peptides on a few pages, as a PDF. We’ll also email you when a peptide’s approval status or dosing changes.
More in Growth hormone
Stacks that include Tesamorelin
Compare Tesamorelin
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.